Mounjaro and Finasteride Interaction: What Patients and Clinicians Need to Know

Do Mounjaro and finasteride interact directly?

Finasteride does not appear in the Mounjaro Drug Interactions section. That section covers two areas: insulin secretagogues or insulin, where the risk of hypoglycemia may call for a lower dose of the secretagogue or insulin, and oral medicines in general, because tirzepatide slows gastric emptying [1].

The finasteride label states that no drug interactions of clinical importance have been identified and that finasteride does not appear to affect the cytochrome P450-linked drug-metabolizing enzyme system. The compounds tested in humans were antipyrine, digoxin, propranolol, theophylline and warfarin, with no clinically meaningful interactions found [2].

Mounjaro is labeled for type 2 diabetes in adults and in children 10 years and older, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes at high risk for them; it is not labeled for weight loss [1]. The weight-loss results discussed below came from a trial of tirzepatide in adults without diabetes and do not establish a Mounjaro weight-loss indication [1][6]. Finasteride 1 mg (Propecia) is indicated for male pattern hair loss in men, while finasteride 5 mg (Proscar) is indicated for symptomatic benign prostatic hyperplasia in men with an enlarged prostate [4][5].

How each drug is metabolized

Tirzepatide is a once-weekly subcutaneous injection that activates both GIP and GLP-1 receptors [1]. It is metabolized through proteolytic cleavage, beta-oxidation and amide hydrolysis rather than CYP enzymes, with low in-vitro potential to inhibit or induce CYP enzymes [1]. Median time to peak concentration is 24 hours, absolute bioavailability is about 80%, 99% is albumin bound, the half-life is about 5 days, and steady state is reached after 4 weeks of weekly dosing [1].

Finasteride is a competitive, specific inhibitor of Type II 5-alpha-reductase, roughly 100-fold selective for Type II over Type I. It is extensively metabolized in the liver, mainly by CYP3A4, into two metabolites with no more than 20% of its activity. Mean terminal half-life is 5 to 6 hours in men 18 to 60 and 8 hours in men over 70 [2].

These different metabolic pathways do not rule out an absorption effect, because tirzepatide's delay of gastric emptying acts before a tablet is absorbed. Neither label describes a study of finasteride absorption during tirzepatide treatment [1][2].

The one mechanism worth knowing about: delayed gastric emptying

The Mounjaro label says tirzepatide delays gastric emptying and can therefore affect the absorption of oral medicines. It advises caution when oral drugs are given with Mounjaro, and monitoring for medicines that depend on threshold concentrations for efficacy or that have a narrow therapeutic index, with warfarin given as the example [1]. The delay is largest after the first dose and diminishes over time [1].

Tirzepatide labeling illustrates this with acetaminophen: after a first 5 mg dose, acetaminophen peak concentration fell 55% and time to peak was 1 hour later, while at week 6 on 15 mg there was no meaningful effect on peak concentration or time to peak, and total exposure was unchanged [1].

Finasteride is not named among the drugs the Mounjaro label asks clinicians to monitor [1]. The 1 mg tablet produces 65% suppression of serum DHT within 24 hours, and the Type II enzyme complex turns over slowly, with a half-life of about 30 days, so the effect on DHT outlasts the drug's plasma half-life [2].

Finasteride, PSA, and large weight change

Finasteride lowers PSA, which matters when a result is interpreted. In men 18 to 41 taking Propecia 1 mg, mean serum PSA fell from 0.7 to 0.5 ng/mL at month 12 [2]. In older men with benign prostatic hyperplasia taking Proscar 5 mg, PSA falls by about 50% within six months, and the label describes doubling an isolated PSA after 6 months of treatment for comparison with normal ranges [3]. The Propecia label says any confirmed increase from the lowest PSA value while on treatment may signal prostate cancer and should be evaluated, even if the value is still within the normal range for men not taking a 5-alpha reductase inhibitor [2].

Finasteride's hormonal effect is modest: mean circulating testosterone and estradiol rise by about 15% compared with baseline but stay within the physiologic range [2]. Tirzepatide, by contrast, changes body weight substantially in people without diabetes. In SURMOUNT-1, 2,539 adults with obesity or overweight were followed for 72 weeks, and mean weight change was -15.0% with 5 mg, -19.5% with 10 mg and -20.9% with 15 mg versus -3.1% with placebo [6].

What the labels say to watch for

Mounjaro carries a boxed warning for thyroid C-cell tumors and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 [1]. Other labeled warnings include acute pancreatitis, with the instruction to discontinue if pancreatitis is suspected; hypoglycemia when insulin or a sulfonylurea is also used; severe gastrointestinal reactions, with the drug not recommended in severe gastroparesis; acute kidney injury from volume depletion; and acute gallbladder disease [1]. Pulmonary aspiration has been reported during general anesthesia or deep sedation in patients receiving GLP-1 receptor agonists [1]. For anyone using oral hormonal contraceptives, the label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose escalation; non-oral hormonal methods should not be affected [1].

Finasteride is contraindicated in pregnancy, and women who are or may be pregnant should not handle crushed or broken tablets because of the risk to a male fetus [2]. In three 12-month controlled trials, 3.8% of men on Propecia reported one or more drug-related sexual adverse reactions versus 2.1% on placebo, with rates falling to 0.3% or lower by year five [2]. The postmarketing section also lists depression and suicidal ideation and behavior, and sexual dysfunction that continued after discontinuation, with the standard note that such voluntary reports cannot establish a causal relationship [2].